Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 936-937

  Reda, Gianluigi ^a   Maura, Francesco ^b   Gritti, Giuseppe ^c   Gregorini, Anna ^b   Binda, Francesca ^b   Guidotti, Francesca ^b   Piciocchi, Alfonso ^d   Visco, Carlo ^e   Rodeghiero, Francesco ^e   Cortelezzi, Agostino ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d GIMEMA Data Center   (Italy)

^e SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; IMMUNOGLOBULIN; LAMIVUDINE;

ADULT; AGED; ANTIVIRAL THERAPY; BLEEDING; BONE MARROW EXAMINATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DRUG SAFETY; HEMOLYTIC ANEMIA; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LATENT VIRUS INFECTION; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES;

EID: 84865381466     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23268     Document Type: Letter

References (21)

1. Visco C, Ruggeri M, Laura EM, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111: 1110-1116.
2. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: Prevalence, clinical associations, and prognostic significance. Blood 2010; 116: 4771-4776.
3. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011; 118: 6299-6305.
4. Gribben JG, Hallek M. Rediscovering alemtuzumab: Current and emerging therapeutic roles. Br J Haematol 2009; 144: 818-831.
5. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011; 25: 1-9.
6. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151-153.
7. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
8. Hillmen P, Skotnicki AB, Robak T, et al Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
9. Shvidel L, Braester A, Bairey O, et al. Survival trends among 1, 325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. Am J Hematol 2011; 86: 985-992.
10. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574.
11. Keating MJ, Flinn I, Jain, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002; 99: 3554-3561.
12. Rai K R, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
13. Stilgenbauer S andDohner H. Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
14. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
15. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
16. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010; 23: 47-59.
17. Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: A systematic review. Haematologica 2011; 96: 752-761.
18. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): Results of a prospective, single-arm multicentre study. Leukemia 2009; 23: 2027-2033.
19. Cortelezzi A, Gritti G, Laurenti L, et al. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol 2011; 156: 481-489.
20. Gritti G, Reda G, Maura F, et al. Low dose alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia patients. Leuk Lymphoma 2012; 53: 424-429.
21. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.